Spruce Biosciences Phase 2 POWER trial shows tildacerfont reduces DHEAS (p=0.020) and increases SHBG (p=0.012) in PCOS

SPRUCE BIOSCIENCES, INC.

27 women with PCOS enrolled; tildacerfont titrated to 200 mg QD vs placebo for 12 weeks.
In patients with elevated baseline DHEAS, geometric mean ratio vs placebo was 0.828 (p=0.020).
SHBG increased 32.9% vs placebo -8.1% (LS mean ratio 1.446, p=0.012).
Tildacerfont well-tolerated; no serious adverse events reported.
Primary endpoint not powered for significance; results suggest therapeutic potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.